EBRElectronic Batch Record

An Electronic Batch Record (EBR) is the validated electronic instance of the batch manufacturing record for one specific batch of regulated product. It is the legal evidence under 21 CFR 211.188 (drugs), 21 CFR 820.184 (medical devices, where it is called the Device History Record), 21 CFR 111.260 (dietary supplements), 21 CFR 117.135 (food preventive controls), and EU GMP Chapter 4 §4.20 (EU drugs) that the batch was manufactured according to the approved Master Batch Record (MBR) and that the resulting product meets the predetermined specifications.

The EBR system performs four functions that paper batch records cannot. It enforces the MBR — the operator cannot execute steps out of sequence, cannot enter values outside MBR-defined limits without raising a deviation, cannot proceed until the prior step is signed. It captures data automatically from connected equipment and laboratory systems — temperatures, weights, pressures, test results — eliminating transcription error. It pre-validates every value at capture — values outside spec trigger an exception in real time rather than three weeks later in QA review. It produces an audit trail compliant with 21 CFR Part 11 §11.10(e) — who did what, when, why, with original-value retention for any change.

Three regulatory threads must be satisfied simultaneously. First, the underlying record requirement — 21 CFR 211.188 lists exactly what a batch production and control record must contain (component identification, weights and measurements, equipment ID, in-process and laboratory control results, manufacturing date, person performing each step, person verifying each step, results of investigation of discrepancies). EU GMP Chapter 4 is equivalent. Second, the electronic-records framework — 21 CFR Part 11 (US) and EU GMP Annex 11 (EU) define the controls required when those records are kept electronically. Third, the data-integrity principles — FDA's 2018 final guidance, MHRA's data-integrity guidance, and PIC/S PI 041-1 codify ALCOA+ (attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, available).

An EBR system that satisfies the underlying record requirement but fails Part 11 (no audit trail, weak access control, no e-signature meaning) is non-compliant. An EBR system that satisfies Part 11 but fails ALCOA+ (audit trail can be bypassed, original values can be overwritten) is non-compliant. The three threads weave together — no single one is sufficient.

Paper batch records carry an inherent review burden. A typical pharmaceutical batch record runs 80-200 pages with 1,000-2,000 individual entries (weights, signatures, in-process checks, equipment status). QA reviews line by line, verifying every value against the spec and every signature against the training record. Median paper review time is 8-12 hours per batch; the variability is the reason batch release cycles run 14-30 days.

Review by exception flips the model. The EBR system pre-validates every captured value at the moment of capture against the MBR-defined limits, the user's authorisation, and the sequence rules. Values inside limits, signed by authorised personnel, in the correct sequence, never reach a reviewer. QA review surfaces only the exceptions — out-of-limit values, manual overrides, deviations, missed steps, late signatures. A typical batch produces 5-15 exceptions; review time drops to 30-90 minutes. Release cycle compresses to 2-5 days.

Every exception in an EBR is, by definition, a candidate deviation. The strongest implementations capture context automatically at exception time — the batch step, the MBR-defined limit, the actual value, the equipment state, the in-process data leading up to the exception, the operator on the line — and pre-populate the deviation record with that context. The operator's burden is the free-text description of what happened and why; the system carries the data context forward.

The deviation then routes through the standard CAPA workflow: investigation, root-cause analysis, corrective action, effectiveness verification. The EBR system holds the linkage from batch step → exception → deviation → CAPA across the product lifecycle, so a trend review can ask 'what fraction of our batches have a Step 12 weight exception?' or 'which deviations link back to the same root cause?'.

An EBR isolated from the rest of the manufacturing IT stack delivers a fraction of its potential value. The standard integration set:

• MES (Manufacturing Execution System) — shop-floor scheduling, material genealogy, dispatch lists. ISA-95 Level 3 protocols (B2MML, OPC UA).
• LIMS (Laboratory Information Management System) — in-process and release test results. Test orders dispatched from EBR; results returned automatically and validated against spec.
• ERP (Enterprise Resource Planning) — material consumption posting, lot release decisions, finished goods receipt. SAP, Oracle, Dynamics most common.
• SCADA / DCS / standalone equipment — direct capture of process parameters via OPC UA, MQTT, or vendor-specific protocols. Eliminates manual entry of weights, temperatures, pressures.
• Electronic document management — MBR templates, SOPs, training records linked from within the batch step context.
• QMS — deviations, CAPAs, change controls, training records linked bidirectionally with the batch execution.

The integration architecture decides what is possible. The most common failure mode is buying an EBR with elegant native interfaces and discovering that the existing equipment is on protocols the EBR vendor does not natively support. Validate the protocol coverage on the actual equipment list before vendor selection.

Computer System Validation (CSV) for an EBR has historically been document-heavy: URS, FRS, FDS, IQ, OQ, PQ, traceability matrix, validation summary report, often 500-1,500 pages per EBR project. FDA's September 2022 draft guidance on Computer Software Assurance (CSA) signals a shift to risk-based testing — high-risk functions get rigorous testing, low-risk functions get lighter assurance, and unscripted exploratory testing is acceptable for low-risk areas. EU GMP Annex 11 has supported risk-based validation since 2015 and ISPE GAMP 5 Second Edition (2022) codifies the approach across categories 1-5.

The validation deliverable set for a modern EBR rollout: validation plan; risk assessment per system function; URS-to-test traceability; IQ for the platform installation; OQ for the platform functions; PQ in the production environment with real batches; validation summary report; ongoing periodic review cadence; change-control linkage so that any future configuration change re-triggers the relevant validation scope. The validated state is not a one-time achievement — Annex 11 §11 expects periodic review to confirm the system remains valid.

• Audit trail can be disabled by a user with administrative rights — Part 11 violation; ALCOA+ failure.
• Original values can be overwritten without retention of the prior value and the change reason.
• E-signatures lack the meaning of the signature — Part 11 §11.50 requires the signed meaning (reviewed, approved, performed) to be unambiguous.
• MBR template change control is weaker than paper. Every MBR version must be permanently linked to the batches executed against it.
• Exceptions are suppressed by widening MBR limits to reduce the review burden rather than tightening process control.
• Validation package treats the EBR as a single system rather than an integrated set — the integration interfaces are where most data-integrity findings originate.
• Periodic review absent or perfunctory — Annex 11 §11 is explicit and inspectors frequently sample for it.